230 likes | 795 Views
PCSK9 Mutations. PCSK9 Loss-of-function Mutations. 2013 ACC/AHA Cholesterol Guidelines 4 Major Statin Benefit Groups. PCSK9 Monoclonal Antibodies. MENDEL Evolocumab Monotherapy for H ypercholesterolemia. LAPLACE-2 Study Design. LAPLACE-2 LDL-C Response at Mean of Weeks 10 and 12.
E N D
2013 ACC/AHA Cholesterol Guidelines4 Major Statin Benefit Groups
GAUSS-2Percent Change in LDL-C From Baseline at Week 12 in Statin-Intolerant Patients
DESCARTESPercent Change in LDL-C From Baseline at Week 52 in Patients With Hypercholesterolemia